GE Healthcare has launched a new Protein A chromatography resin, MabSelect PrismA, which the company said will help biopharmaceutical manufacturers improve their monoclonal antibody (mAb) purification capacity by up to 40%. Between 2017 and 2022, GE is annually investing up to $70 million to increase capacity in its production facility at its life-sciences site in Uppsala, Sweden, where the MabSelect PrismA has been developed and where the resin is manufactured.

GE said the resin is more alkaline-stable, and as a result, MabSelect PrismA can be cleaned with a higher concentration of sodium hydroxide to better control cross-contamination and bioburden risks.

Source: GE Healthcare